Endocrine Abstracts

Objectives: Delayed puberty is thought to be common in boys with Duchenne muscular dystrophy [DMD]. To date, studies addressing its frequency are not available. This study aims to report the frequency of delayed puberty in DMD from clinical examination.Methods: All boys with DMD aged at least 14 years in January 2022 known to the Glasgow paediatric neuromuscular service (2015-2022) were included. Thirty-seven boys were identified. All 37 boys had at leas...

Introduction: There is a need to understand testicular development in adolescents with Duchenne Muscular Dystrophy (DMD).Objective: To evaluate testicular development and function in DMD over 12 months.Methods: All data are presented as median(range). 23 boys aged 12.4 years (10.0, 16.8) with a bone age delay of 0.9 years (−2.4, 7.1) had physical and biochemical assessment of puberty at Month 0(M0) and Month 12(M12) and divid...

Background: Glucocorticoid (GC) therapy is the standard management for Duchenne Muscular Dystrophy (DMD), but its use is associated with significant side effects, including weight gain. Limited research exists on the impact of GC initiation on body composition in DMD, particularly regarding the timing of fat mass increase.Objective: This study aimed to assess changes in growth parameters, namely height-SDS, weight-SDS, b...

Background: Obesity is common in young people with Duchenne Muscular Dystrophy (DMD) and may lead to abnormalities of glucose homeostasis and insulin resistance. Annual measurement of HbA1c and sex hormone binding globulin (SHBG), shown to be inversely related to insulin levels, was introduced as local clinical monitoring in 2022. This report is an audit against our local guidance and service evaluation.Methods: Based on the American Academy Paediatrics ...